Comment
doi: 10.7326/ACPJ201902190-021.
In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks
- PMID: 30776810
- DOI: 10.7326/ACPJ201902190-021
Item in Clipboard
Comment
In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks
Ann Intern Med.
.
No abstract available
Comment on
-
On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.Ann Intern Med. 2018 Nov 20;169(10):694-703. doi: 10.7326/M18-0517. Epub 2018 Oct 30. Ann Intern Med. 2018. PMID: 30383134 Clinical Trial.
Similar articles
-
On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.Ann Intern Med. 2018 Nov 20;169(10):694-703. doi: 10.7326/M18-0517. Epub 2018 Oct 30. Ann Intern Med. 2018. PMID: 30383134 Clinical Trial.
-
Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study.J Am Acad Dermatol. 2018 Jan;78(1):189-190. doi: 10.1016/j.jaad.2017.08.018. J Am Acad Dermatol. 2018. PMID: 29241781 Clinical Trial. No abstract available.
-
Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.Arthritis Rheum. 2011 Mar;63(3):775-82. doi: 10.1002/art.30195. Arthritis Rheum. 2011. PMID: 21360507 Clinical Trial.
-
Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers.Curr Opin Rheumatol. 2016 Nov;28(6):577-85. doi: 10.1097/BOR.0000000000000332. Curr Opin Rheumatol. 2016. PMID: 27541182 Review.
-
Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.Vasa. 2016;45(3):201-12. doi: 10.1024/0301-1526/a000526. Vasa. 2016. PMID: 27129065 Review.
Cited by
-
Vasodilators for primary Raynaud's phenomenon.Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4. Cochrane Database Syst Rev. 2021. PMID: 33998674 Free PMC article.
-
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD014089. doi: 10.1002/14651858.CD014089. Cochrane Database Syst Rev. 2023. PMID: 37929840 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
